Literature DB >> 28604701

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Christiane R Stadler1, Hayat Bähr-Mahmud1, Leyla Celik1, Bernhard Hebich1, Alexandra S Roth1, René P Roth1, Katalin Karikó1, Özlem Türeci2, Ugur Sahin1,3,4.   

Abstract

The potential of bispecific T cell-engaging antibodies is hindered by manufacturing challenges and short serum half-life. We circumvented these limitations by treating mice with in vitro-transcribed pharmacologically optimized, nucleoside-modified mRNA encoding the antibody. We achieved sustained endogenous synthesis of the antibody, which eliminated advanced tumors as effectively as the corresponding purified bispecific antibody. Because manufacturing of pharmaceutical mRNA is fast, this approach could accelerate the clinical development of novel bispecific antibodies.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28604701     DOI： 10.1038/nm.4356

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  19 in total

1.  Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.

Authors:  Silke Holtkamp; Sebastian Kreiter; Abderraouf Selmi; Petra Simon; Michael Koslowski; Christoph Huber; Ozlem Türeci; Ugur Sahin
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

2.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

Authors:  Katalin Karikó; Hiromi Muramatsu; Frank A Welsh; János Ludwig; Hiroki Kato; Shizuo Akira; Drew Weissman
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

Review 3.  Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond.

Authors:  Britta Vallazza; Sebastian Petri; Marco A Poleganov; Florian Eberle; Andreas N Kuhn; Ugur Sahin
Journal:  Wiley Interdiscip Rev RNA       Date:  2015-06-09       Impact factor: 9.957

4.  Bispecific antibodies rise again.

Authors:  Ken Garber
Journal:  Nat Rev Drug Discov       Date:  2014-11       Impact factor: 84.694

5.  The use of hybrid hybridomas to target human cytotoxic T lymphocytes.

Authors:  A Lanzavecchia; D Scheidegger
Journal:  Eur J Immunol       Date:  1987-01       Impact factor: 5.532

6.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

7.  The tobacco etch viral 5' leader and poly(A) tail are functionally synergistic regulators of translation.

Authors:  D R Gallie; R L Tanguay; V Leathers
Journal:  Gene       Date:  1995-11-20       Impact factor: 3.688

8.  Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.

Authors:  Patrick Micke; Johanna Sofia Margareta Mattsson; Karolina Edlund; Miriam Lohr; Karin Jirström; Anders Berglund; Johan Botling; Jörg Rahnenfuehrer; Millaray Marincevic; Fredrik Pontén; Simon Ekman; Jan Hengstler; Stefan Wöll; Ugur Sahin; Ozlem Türeci
Journal:  Int J Cancer       Date:  2014-04-08       Impact factor: 7.396

9.  Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.

Authors:  Ugur Sahin; Michael Koslowski; Karl Dhaene; Dirk Usener; Gunda Brandenburg; Gerhard Seitz; Christoph Huber; Ozlem Türeci
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

10.  Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6.

Authors:  Christiane R Stadler; Hayat Bähr-Mahmud; Laura M Plum; Kathrin Schmoldt; Anne C Kölsch; Özlem Türeci; Ugur Sahin
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110
View more
  66 in total

Review 1.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 2.  The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy.

Authors:  Jessica B Foster; David M Barrett; Katalin Karikó
Journal:  Mol Ther       Date:  2019-02-02       Impact factor: 11.454

Review 3.  mRNA: A Novel Avenue to Antibody Therapy?

Authors:  Thomas Schlake; Moritz Thran; Katja Fiedler; Regina Heidenreich; Benjamin Petsch; Mariola Fotin-Mleczek
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

4.  Immunotherapy perspectives in the new era of B-cell editing.

Authors:  Natsuko Ueda; Marine Cahen; Yannic Danger; Jérôme Moreaux; Christophe Sirac; Michel Cogné
Journal:  Blood Adv       Date:  2021-03-23

5.  Cancer: mRNA-encoded bispecific antibodies eliminate tumours.

Authors:  Sarah Crunkhorn
Journal:  Nat Rev Drug Discov       Date:  2017-07-31       Impact factor: 84.694

Review 6.  Bispecific antibodies in cancer immunotherapy.

Authors:  Christoph Rader
Journal:  Curr Opin Biotechnol       Date:  2019-12-13       Impact factor: 9.740

7.  Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Authors:  Christiane R Stadler; Hayat Bähr-Mahmud; Leyla Celik; Bernhard Hebich; Alexandra S Roth; René P Roth; Katalin Karikó; Özlem Türeci; Ugur Sahin
Journal:  Nat Med       Date:  2017-10-06       Impact factor: 53.440

8.  Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity.

Authors:  Katarzyna C Pituch; Markella Zannikou; Liliana Ilut; Ting Xiao; Michael Chastkofsky; Madina Sukhanova; Nicola Bertolino; Daniele Procissi; Christina Amidei; Craig M Horbinski; Karen S Aboody; C David James; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 9.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

10.  Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.

Authors:  Annika M Frank; Angela H Braun; Lea Scheib; Shiwani Agarwal; Irene C Schneider; Floriane Fusil; Séverine Perian; Ugur Sahin; Frederic B Thalheimer; Els Verhoeyen; Christian J Buchholz
Journal:  Blood Adv       Date:  2020-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.